Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Meta Expands AI Training With Employee Activity Tracking Tools 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
IRVINE, Calif., May 23, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX). Investors who purchased or otherwise acquired shares between March 30, 2017 and May 11, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before the July 11, 2017 lead plaintiff motion deadline.
If you purchased Akari shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose that: Chief Executive Officer Dr. Gur Roshwalb and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; that Akari lacked adequate checks and protections to prevent such behavior; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On May 11, 2017, Akari announced that Dr. Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and subsequently withdrawn in April 26, 2017 by Edison Investment Research Ltd. When this information was released, Akari shares fell in value materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
